{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T06:35:04Z","timestamp":1768890904966,"version":"3.49.0"},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"01","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":3793,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Nucl Med"],"published-print":{"date-parts":[[2012,1]]},"abstract":"<jats:p>Ablative approaches using radioiodine are increasingly proposed for the treatment of Graves\u2032 disease (GD) but their ophthalmologic and biological autoimmune responses remain controversial and data concerning clinical and biochemical outcomes are limited. The aim of this study was to evaluate thyroid function, TSH-receptor antibodies (TRAb) and Graves\u2032 ophthalmopathy (GO) occurrence after radioiodine thyroid ablation in GD. We reviewed 162 patients treated for GD by iodine-131 (131 I) with doses ranging from 370 to 740 MBq, adjusted to thyroid uptake and sex, over a 6-year period in a tertiary referral center. Collected data were compared for outcomes, including effectiveness of radioiodine therapy (RIT) as primary endpoint, evolution of TRAb, and occurrence of GO as secondary endpoints. The success rate was 88.3% within the first 6 months after the treatment. The RIT failure was increased in the presence of goiter (adjusted odds ratio = 4.1, 95% confidence interval 1.4-12.0, P = 0.010). The TRAb values regressed with time (r = \u22120.147; P = 0.042) and patients with a favorable outcome had a lower TRAb value (6.5 \u00b1 16.4 U\/L) than those with treatment failure (23.7 \u00b1 24.2 U\/L, P &lt; 0.001). At the final status, 48.1% of patients achieved normalization of serum TRAb. GO occurred for the first time in 5 patients (3.7%) who were successfully cured for hyperthyroidism but developed early and prolonged period of hypothyroidism in the context of antithyroid drugs (ATD) intolerance (P = 0.003) and high TRAb level (P = 0.012). On the basis the results of this study we conclude that ablative RIT is effective in eradicating Graves\u2032 hyperthyroidism but may be accompanied by GO occurrence, particularly in patients with early hypothyroidism and high pretreatment TRAb and\/or ATD intolerance. In these patients, we recommend an early introduction of LT4 to reduce the duration and the degree of the radioiodine-induced hypothyroidism.<\/jats:p>","DOI":"10.4103\/1450-1147.98731","type":"journal-article","created":{"date-parts":[[2012,7,19]],"date-time":"2012-07-19T12:55:26Z","timestamp":1342702526000},"page":"7-11","source":"Crossref","is-referenced-by-count":17,"title":["Radioiodine Thyroid Ablation in Graves\u2032 Hyperthyroidism: Merits and Pitfalls"],"prefix":"10.1055","volume":"11","author":[{"given":"J.","family":"Nwatsock","sequence":"additional","affiliation":[{"name":"Service Central de Biophysique et de M\u00e9decine Nucl\u00e9aire, CHU de la Timone; 264 Rue Saint, Pierre 13385 Marseille Cedex 5, France"},{"name":"Service de M\u00e9decine Nucl\u00e9aire, H\u00f4pital G\u00e9n\u00e9ral de Yaound\u00e9; BP: 5408 Yaound\u00e9, Cameroun"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Taieb","sequence":"additional","affiliation":[{"name":"Service Central de Biophysique et de M\u00e9decine Nucl\u00e9aire, CHU de la Timone; 264 Rue Saint, Pierre 13385 Marseille Cedex 5, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Tessonnier","sequence":"additional","affiliation":[{"name":"Service Central de Biophysique et de M\u00e9decine Nucl\u00e9aire, CHU de la Timone; 264 Rue Saint, Pierre 13385 Marseille Cedex 5, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mancini","sequence":"additional","affiliation":[{"name":"Service d\u2032Epid\u00e9miologie, CHU de la Timone; 264 Rue Saint, Pierre 13385 Marseille Cedex 5, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Dong-A-Zok","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Nucl\u00e9aire, H\u00f4pital G\u00e9n\u00e9ral de Yaound\u00e9; BP: 5408 Yaound\u00e9, Cameroun"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Mundler","sequence":"additional","affiliation":[{"name":"Service Central de Biophysique et de M\u00e9decine Nucl\u00e9aire, CHU de la Timone; 264 Rue Saint, Pierre 13385 Marseille Cedex 5, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,5,21]]},"container-title":["World Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.4103\/1450-1147.98731.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T22:46:09Z","timestamp":1653173169000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.4103\/1450-1147.98731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":0,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2022,5,21]]},"published-print":{"date-parts":[[2012,1]]}},"URL":"https:\/\/doi.org\/10.4103\/1450-1147.98731","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1450-1147","1607-3312"],"issn-type":[{"value":"1450-1147","type":"print"},{"value":"1607-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}